Previous 10 | Next 10 |
Selvita to acquire Fidelta from Galapagos PR Newswire MECHELEN, Belgium and KRAKOW, Poland, Nov. 23, 2020 Strengthening Selvita's position as one of the largest preclinical contract research organizations in Europe Acquisition substantially expands Se...
Mechelen, Belgium; 9 November 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first psoriasis patient in the Phase 1b trial with GLPG3667. GLPG3667 is a proprietary compound with an undisclosed mechanism of action in development for inflam...
Galapagos NV (GLPG) Q3 2020 Results Conference Call November 06, 2020 08:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - Chief Executive Officer Andre Hoekema - Chief Business Officer Bart Filius - Chief Operating and Financial Officer Walid Abi-Saab ...
The following slide deck was published by Galapagos NV in conjunction with their 2020 Q3 earnings call. For further details see: Galapagos NV 2020 Q3 - Results - Earnings Call Presentation
Galapagos (GLPG): Q3 GAAP EPS of -€3.81.Revenue of €368.6M (-51.0% Y/Y).FY2020 guidance: operational cash burn of €490M-€520M. In the 4Q, the company expects to report topline data from the PINTA Phase 2 study with GLPG1205 in IPF.Press Release For furt...
Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collaboration and license agreement for the global development and commercialization...
First nine months 2020 financial results: Group revenues and other income of €368.6 million Operating loss of €163.2 million Net loss of €247.6 million Cash and current financial investments of €5.3 billion on 30 September 2020...
Palm Beach, FL – November 5, 2020 – During the present global pandemic, certain industries have actually grown… the global UV disinfection market is one of those industries. New product manufacturing has increased since the outbreak of the COVID-19 pandemic equipment th...
Gilead Sciences (GILD) and collaboration partner Galapagos NV (GLPG) announce that the European Medicines Agency ((EMA)) has accepted for review the latter's marketing application seeking approval to use Jyseleca (filgotinib) to treat adults with moderately to severely active ulcerative colit...
-- Application Based on Results from Pivotal Phase 2b/3 SELECTION Trial -- Foster City, Calif., & Mechelen, Belgium, November 2, 2020, 22.01 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the applicatio...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...